NicolsonNG,MurthaTD,DongW,PaulssonJO,ChoiJ,BarbieriAL, 2018.Comprehensive genetic analysis of follicular thyroid carcinoma predicts prognosis independent of histology,J Clin Endocrinol Metab 103 2640 -50
MishraA,KumarC,ChandG,AgarwalG,AgarwalA,VermaAK, 2016.Long-term outcome of follicular thyroid carcinoma in patients undergoing surgical intervention for skeletal metastases,World J Surg 40 562 -9
StensonG,NilssonIL,MuN,LarssonC,LundgrenCI,JuhlinCC, 2016.Minimally invasive follicular thyroid carcinomas: prognostic factors,Endocrine 53 505 -11
SponzielloM,LavaroneE,PegoloE,DiLC,PuppinC,RussoMA, 2013.Molecular differences between human thyroid follicular adenoma and carcinoma revealed by analysis of a murine model of thyroid cancer,Endocrinology 154 3043 -53
BrownC,ManganoW,ThompsonS,RichmondB, 2018.Factors predicting thyroid malignancy in fine needle aspiration biopsy specimens classified as atypia of uncertain significance/ follicular lesion of uncertain significance,Am Surg 84 1207 -13
Abu-SinnaE,HasanMY,El-DeftarMM,AmerSA,AbdelsalamLO,NakhlaJA, 2018.Galectin-3 and HBME-1 expression on agarose cell blocks from fine-needle aspirates of follicular cell-derived thyroid tumors,J Cytol 35 27 -32
MurtezaogluAR,GucerH, 2017.Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1,and cytokeratin 19. Pol J Pathol 68 1 -10
ArcoliaV,JourneF,RenaudF,LeteurtreE,GabiusHJ,RemmelinkM, 2017.Combination of galectin-3, CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer,Oncol Lett 14 4183 -9
MoyanoL,FrancoC,CarreñoL,RobinsonP,SánchezG., 2004.HBME-1 and cyclin D1 as diagnostic markers for follicular thyroid carcinoma,Rev Med Chil 132 279 -84
CheahWK, 2007.Thyroid cancer: diagnosis and management,Singapore Med J 48 107 -12
LenggenhagerD,MaggioEM,MochH,Rössle M. HBME, 2013.-1 expression in hyalinizing trabecular tumours of the thyroid gland,Histopathology 62 1092 -7
TollenaarRA,van KriekenJH,van SlootenHJ,BruinvelsDJ,NelemansKM,van den BroekLJ, 1998.Immunohistochemical detection of p53 and Bcl-2 in colorectal carcinoma: No evidence for prognostic significance,Br J Cancer 77 1842 -7
LiuZ,ZhouG,NakamuraM,KoikeE,LiY,OzakiT, 2011.Encapsulated follicular thyroid tumor with equivocal nuclear changes, so-called well-differentiated tumor of uncertain malignant potential: A morphological, immunohistochemical, and molecular appraisal,Cancer Sci 102 288 -94
JeongSH,HongHS,LeeEH, 2016.Can nodular hyperplasia of the thyroid gland be differentiated from follicular adenoma and follicular carcinoma by ultrasonography?,Ultrasound Q 32 349 -55
CossuA,LissiaA,DedolaMF,DeianaA,FaeddaR,PalmieriG, 2005.Classic follicular dendritic reticulum cell tumor of the lymph node developing in a patient with a previous inflammatory pseudotumor-like proliferation,Hum Pathol 3 207 -11
PfeiferA,WojtasB,Oczko-WojciechowskaM,KukulskaA,CzarnieckaA,EszlingerM, 2013.Molecular differential diagnosis of follicular thyroid carcinoma and adenoma based on gene expression profiling by using formalin-fixed paraffinembedded tissues,BMC Med Genomics 6 38 -
RezkS,KhanA, 2005.Role of immunohistochemistry in the diagnosis and progression of follicular epithelium-derived thyroid carcinoma,Appl Immunohistochem Mol Morphol 13 256 -64
OmiY,ShibataN,OkamotoT,ObaraT,KobayashiM., 2012.The role of CD147 in the invasiveness of follicular thyroid carcinoma cells,Thyroid 22 383 -94
De MatosPS,FerreiraAP,DeOFF,AssumpçãoLV,MetzeK,WardLS, 2005.Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy,Histopathology 47 391 -401
CaseyMB,LohseCM,LloydRV, 2003.Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1,Endocr Pathol 14 55 -60
ColiA,BigottiG,ParenteP,FedericoF,CastriF,MassiG, 2007.Atypical thyroid nodules express both HBME-1 and galectin-3, two phenotypic markers of papillary thyroid carcinoma,J Exp Clin Cancer Res 26 221 -7
ZhuX,SunT,LuH,ZhouX,LuY,CaiX, 2010.Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma,J Clin Pathol 63 786 -9